AI assistant
Advanced Enzyme Technologies Limited Earnings Release 2026
62369_rns_2026-05-09_51a493d3-f44b-463a-a7c3-9f0387db027a.pdf
Earnings Release
Open in viewerOpens in your device viewer
advanced enzymes
Where ENZYME is Life
Advanced Enzyme Technologies Ltd.
CIN: L24200MH1989PLC051018
Sun Magnetica, 'A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India
Tel: +91-22-4170 3200, Fax: +91-22-2583 5159
Email: [email protected], www.advancedenzymes.com
May 09, 2026
BSE Limited
P. J. Towers,
Dalal Street,
Mumbai- 400 001
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1,
G Block, Bandra-Kurla Complex,
Bandra (E) Mumbai- 400 051
Scrip Code-540025
Trading Symbol-ADVENZYMES
Subject: Press Release
Ref: ISIN: INE837H01020
Dear Sir/Madam,
Pursuant to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed is Press Release, titled "Quarterly Earnings Release" dated May 09, 2026.
This is for your information and for public at large.
Thanking you,
Yours faithfully,
For Advanced Enzyme Technologies Limited
SANJAY
Digitally signed by
SANJAY PRAKASH
BASANTANI
Date: 2026.05.09
14:38:42 +00'30'
Sanjay Basantani
Company Secretary and Head – Legal
Encl.: As above
WELCOME TO THE WORLD OF BETTER BUSINESS
Factory: Plot No. A-61/62, MIDC Malegaon, Tal. Sinnar, Dist. Nashik - 422 113. Maharashtra, India. Tel.: +91-99701 00750 / +91-2551-230 044, Fax: +91-2551-230 816
advancedenzymes
www.ifcnet.com
FOR IMMEDIATE RELEASE
QUARTERLY EARNINGS RELEASE
Thane, India: Saturday, May 09, 2026
Advanced Enzyme Technologies Limited announces Financial Results for Fourth Quarter and Year ended March 2026
Advanced Enzyme Technologies Limited (Advanced Enzymes; NSE: ADVENZYMES; BSE: 540025), a leading specialty biotech company, with global leadership in the manufacturing of enzymes & probiotics, today announced their audited financial results for fourth quarter and year ended March 2026.
CONSOLIDATED QUARTERLY FINANCIAL HIGHLIGHTS:
| (Amount in INR Mn.) | Q4 FY26 | Q3 FY26 | Q4 FY25 | Change (Y-o-Y %) | Change (Q-o-Q %) | FY26 | FY25 | Change (%) |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,034 | 1,719 | 1,672 | +22% | +18% | 7,458 | 6,369 | +17% |
| EBITDA | 632 | 494 | 456 | +39% | +28% | 2,291 | 1,944 | +18% |
| EBITDA Margin (%) | 31% | 29% | 27% | 31% | 31% | |||
| PAT | 453 | 432 | 267 | +69% | +5% | 1,736 | 1,340 | +30% |
| PAT Margin (%) | 22% | 25% | 16% | 23% | 21% | |||
| EPS | 3.84 | 3.80 | 2.37 | +62% | +1% | 15.08 | 11.72 | +29% |
CONSOLIDATED FINANCIAL REVIEW (Y-o-Y basis):
Revenue from Operations:
Revenue from operations on consolidated basis increased to ₹ 2,034 million in Q4 FY26 from ₹ 1,672 million in Q4 FY25, a growth of 22%.
Profit:
Consolidated EBITDA during Q4 FY26 stands at ₹ 632 million as compared to ₹ 456 million during Q4 FY25, increase of 39%.
Profit before tax stands at ₹ 598 million during Q4 FY26 as against ₹ 435 million in Q4 FY25, an increase of 38%.
Profit after tax grew by 69% and stands at ₹ 453 million during Q4 FY26 as compared to ₹ 267 million during Q4 FY25.
Margin:
EBITDA margin stands at 31%, PBT margin stands at 29% and PAT margin stands at 22% during the quarter.
Financial Costs:
Financial costs stood at ₹ 6 million during Q4 FY26 as against ₹ 8 million in Q4 FY25.
Depreciation and Amortization:
Depreciation and Amortization charge for Q4 FY26 stood at ₹ 102 million as compared to ₹ 101 million in the same quarter previous year.
Earnings Per Share:
Earnings Per Share for Q4 FY26 stands at ₹ 3.84 as compared to ₹ 2.37 in Q4 FY25.
www.advancedenzymes.com
advancedenzymes
where i NEFAR is i life
OPERATIONAL PERFORMANCE REVIEW:
Segmental Revenue:
| (Amount in INR Mn.) | Q4 FY26 | Q4 FY25 | Change (%) |
|---|---|---|---|
| Human Nutrition | 1,281 | 1,031 | +24% |
| Animal Nutrition | 250 | 209 | +19% |
| Bio-Processing | 324 | 278 | +17% |
| Specialized Manufacturing | 180 | 154 | +17% |
The total revenue from operations grew by 22% on y-o-y basis and 18% on q-o-q basis.
Revenue from the Human Nutrition segment increased by 24%, reaching ₹ 1,281 million in Q4 FY26, compared to ₹ 1,031 million in Q4 FY25. This growth is on account of increased activities in the Pharma/API and Bio-catalysis business.
The Animal nutrition delivered a strong growth of 19% to ₹ 250 million in Q4 FY26 as against ₹ 209 million in Q4 FY25.
The Bio-Processing segment recorded growth of 17% during the quarter, reaching ₹ 324 million in Q4 FY26, compared to ₹ 278 million in Q4 FY25. This growth was primarily driven by the Food business, which surged 20% y-o-y to ₹ 276 million in Q4 FY26. In contrast, the Non-Food business marginally declined by 1%, standing at ₹ 47 million for the quarter.
The Specialized Manufacturing segment grew by 17%, amounting to ₹ 180 million during the quarter.
Geographical Revenue:
- India
- Americas
- Europe
- Asia (ex-India)
- Rest of the world
Domestic sales accounted for ₹ 1,061 million in Q4 FY26 as compared to ₹ 704 million in Q4 FY25, higher by 51%.
The total revenue includes international sales of ₹ 973 million in Q4 FY26, compared to ₹ 968 million in Q4 FY25, representing a marginal increase of 1% on y-o-y basis. The revenue declined by 11% in the Americas and 7% in Europe. Asia (ex-India) recorded growth of 38% and the rest of the world reported robust growth of 44%.
During Q4 FY26, domestic sales accounted for 52% compared with 42% in Q4 FY25, while international sales accounted for 48% of revenue from operations compared with 58% in Q4 FY25.
www.advancedenzymes.com
advancedenzymes
www.lane.edu
CONSOLIDATED FINANCIAL REVIEW (Q-o-Q basis):
Revenue from Operations:
Revenue from operations on consolidated basis increased to ₹ 2,034 million in Q4 FY26 from ₹ 1,719 million in Q3 FY26, a growth of 18%.
Profit:
Consolidated EBITDA during Q4 FY26 stands at ₹ 632 million as compared to ₹ 494 million during Q3 FY26, higher by 28%.
Profit before tax stands at ₹ 598 million during Q4 FY26 as against ₹ 583 million in Q3 FY26, an increase of 3%
Profit after tax grew by 5% and stands at ₹ 453 million during Q4 FY26 as compared to ₹ 432 million during Q3 FY26.
Financial Costs:
Financial costs stood at ₹ 6 million during Q4 FY26 as against ₹ 6 million in Q3 FY26.
Depreciation and Amortization:
Depreciation and Amortization charge for Q4 FY26 remained unchanged at ₹ 102 million as compared to the last quarter.
Earnings Per Share:
Earnings Per Share for Q4 FY26 stands at ₹ 3.84 as compared to ₹ 3.80 in Q3 FY26.
OPERATIONAL PERFORMANCE REVIEW:
Segmental Revenue:
| (Amount in INR Mn.) | Q4 FY26 | Q3 FY26 | Change (%) |
|---|---|---|---|
| Human Nutrition | 1,281 | 960 | +33% |
| Animal Nutrition | 250 | 244 | +2% |
| Bio-Processing | 324 | 361 | -10% |
| Specialized Manufacturing | 180 | 155 | +16% |
The human nutrition segment grew by 33% to ₹ 1,281 million in Q4 FY26 as compared to ₹ 960 million in Q3 FY26.
The animal nutrition business recorded growth of 2%, reaching ₹ 250 million in Q4 FY26, as compared to ₹ 244 million in Q3 FY26.
The Bio-Processing segment recorded an 10% sequential de-growth, generating ₹ 324 million in Q4 FY26 compared to ₹ 361 million in Q3 FY26. Within this segment, the Food business declined by 11% to ₹ 276 million and the Non-Food business by 7% to ₹ 47 million, compared to the previous quarter.
The Specialized Manufacturing segment delivered a growth of 16%, reaching ₹ 180 million in Q4 FY26, up from ₹ 155 million in Q3 FY26.
Geographical Revenue:
Domestic Sales amounted to ₹ 1,061 million in Q4 FY26, compared to ₹ 801 million in Q3 FY26, reflecting a sequential growth of 32%. Domestic sales accounted for approximately 52% of total revenue from operations, compared to 47% in Q3 FY26.
International Sales grew by 6% to ₹ 973 million in Q4 FY26, up from ₹ 919 million in Q3 FY26. The revenue grew by 14% in Americas, 12% in Asia (ex-India), while the Europe and rest of the world recorded a de-growth of 2% and 43% respectively. International sales represented 48% of total revenue from operations, down from 53% in Q3 FY26.
www.advancedenzymes.com
advancedenzymes
www.ifcnet.com
CONSOLIDATED ANNUAL FINANCIAL REVIEW (YTD basis):
Revenue from Operations:
Revenue from operations on consolidated basis increased to ₹ 7,458 million in FY26 from ₹ 6,369 million in FY25, reported higher by 17%.
Profit:
Consolidated EBITDA during FY26 stands at ₹ 2,291 million as compared to ₹ 1,944 million during FY25, growth of 18%.
Profit before tax stands at ₹ 2,325 million during FY26 as against ₹ 1,874 million in FY25, an increase of 24%.
Profit after tax stands at ₹ 1,736 million during FY26 as compared to ₹ 1,340 million during FY25, an increase of 30%.
Margin:
EBITDA margin stands at 31%, PBT margin stands at 31% and PAT margin stands at 23% during FY26.
Financial Costs:
Financial costs stood at ₹ 26 million during FY26 as against ₹ 36 million in FY25.
Depreciation and Amortization:
Depreciation and Amortization charge for FY26 is ₹ 401 million as compared to ₹ 366 million in FY25.
Earnings Per Share:
Earnings Per Share for FY26 stands at ₹ 15.08 as compared to ₹ 11.72 in FY25.
OPERATIONAL PERFORMANCE REVIEW:
Segmental Revenue:
| (Amount in INR Mn.) | FY26 | FY25 | Change (%) |
|---|---|---|---|
| Human Nutrition | 4,674 | 4,053 | +15% |
| Animal Nutrition | 946 | 760 | +25% |
| Bio-Processing | 1,176 | 1,018 | +16% |
| Specialized Manufacturing | 662 | 539 | +23% |
The Human Nutrition segment reported 15% growth, reaching ₹ 4,674 million in FY26, compared to ₹ 4,053 million in FY25.
The Animal Nutrition segment demonstrated robust growth of 25% to ₹ 946 million in FY26, up from ₹ 760 million in FY25.
The Bio-Processing segment grew by 16% during the year, contributing ₹ 1,176 million in FY26, compared to ₹ 1,018 million in FY25. Within this segment, the Food business accounted for 13% of total revenue, reaching ₹ 967 million, delivering 19% growth, while the Non-Food business contributed 3%, amounting to ₹ 209 million, with marginal growth.
The Specialized Manufacturing segment contributed 9% to the total revenue, growing by 23% during the year, reaching ₹ 662 million in FY26.
www.advancedenzymes.com
advancedenzymes
where home is life
Geographical Revenue:
- India
- Americas
- Europe
- Asia (ex-India)
- Rest of the world
International Sales contributed ₹ 3,731 million in FY26, compared to ₹ 3,464 million in FY25,
reflecting growth of 8% YTD. The revenue declined by 7% in the Americas, while registered healthy growth of 19% in Europe, 53% in Asia (ex-India), and 37% in the rest of the world
Domestic Sales amounted to ₹ 3,727 million in FY26, compared to ₹ 2,905 million in FY25, representing an increase of 28% on YTD basis. Domestic sales contributed approximately 50% of total revenue from operations, up from 46% in FY25, while international sales accounted for the remaining 50%, lower from 54% in FY25.
www.advancedenzymes.com
advancedenzymes
www.lumac.com
OUTLOOK 2026-27
Advanced Enzymes remains committed to enhancing and strengthening its business model by maintaining a strong focus across its three key segments—Human Nutrition, Animal Nutrition, and Bio-Processing. The company is actively working on expanding its product portfolio, particularly in the probiotics space, through ongoing development and new product launches. With its current infrastructure and capital investments, Advanced Enzymes is well-positioned to grow its enzymes and probiotics business.
Human Nutrition:
The Company already operates a successful B2C business in the USA and is now replicating this model in India to drive growth and explore new opportunities. It remains committed to expanding its B2C presence within the Human Nutrition sector. As part of this strategy, the Company has launched its own nutraceutical brand, Wellfa, targeting to Indian consumers. The brand offers a wide range of products, including immune support, skincare, gut health, metabolism enhancement, detox solutions, weight management, stress relief, and respiratory health, among others.
This segment is expected to become a key growth driver for the Company. Additionally, it is selling through other online platforms to diversify and strengthen its digital sales channels.
Animal Nutrition:
In the Animal Nutrition segment, the Company is actively carrying out trials and research to develop innovative and more effective nutritional products aimed at enhancing the performance of animal feeds. Efforts are underway to register and launch additional products in both domestic and international markets. Simultaneously, the Company plans to expand its sales and marketing teams across the USA, MENA, and Asian regions, while also aiming to broaden its global presence by appointing new distributors in international markets.
Probiotics:
The Company continuously make efforts on introducing additional probiotic products in the Human Nutrition segment, focusing on immunity enhancement, active health foods, gut health, and various nutraceutical applications. In the Animal Nutrition segment, it is committed to launching new products aimed at boosting immunity, improving digestion, and enhancing the nutritional value of animal feed.
Bio Catalysis:
The Company has achieved notable progress in developing biocatalysis for API manufacturers, offering targeted enzymatic solutions that help reduce energy consumption, processing time, and chemical usage. Some of these products are at various stages of development, with a few currently in advanced plant-level trials with API manufacturers. This area represents a key opportunity where the Company intends to maintain its focus and ongoing efforts.
Baking:
The Company offers a diverse portfolio of enzymes for the food processing sector and has submitted 15 dossiers to the European Food Safety Authority (EFSA), receiving positive opinions for 9 of them. Its product range demonstrates efficacy and performance on par with leading industry players. With a strong focus on value-driven solutions, the Company is well-positioned to expand its presence across Europe, the Americas, and other global markets, particularly within the baking industry.
Research & Development:
The Company is making substantial investments in state-of-the-art R&D infrastructure, aiming to lead innovation in the formulation of new applications. With a strong focus on expanding its application portfolio across various industries, the Company remains committed to ongoing R&D investment. It also plans to further strengthen its R&D team to support this growth and drive future advancements.
Inorganic expansion:
The Company has a strong track record of inorganic growth, having successfully completed four acquisitions over the past nine years, all financed through internal accruals, maintaining its status as a zero-debt entity. It will continue to explore strategic acquisition opportunities that can enhance its front-end marketing capabilities, expand its geographical footprint, strengthen its product portfolio, and bolster its B2C business.
www.advancedenzymes.com
advancedenzymes
www.avm.es
RESULTS CONFERENCE CALL DETAILS
Advanced Enzymes will hold an earnings conference call on 12th May 2026, Tuesday at 09:00 Hours IST to discuss quarterly performance. The transcript of the call will be available later in the Investor Relations section on the Company's website, www.advancedenzymes.com
Please dial the numbers at least 5-10 minutes prior to the conference schedule to ensure that you are connected on time.
Conference Call Primary Number: +91 86 3416 8438 / +91 86 4536 6489
[Pre-registration link]
For further information, please contact:
Ronak Saraf
Investor Relations
☎ [email protected]
CORPORATE INFORMATION:
Advanced Enzyme Technologies Limited
Regd. Office: 5th Floor, 'A' Wing, Sun Magnetica,
Louiswadi, Thane (W) -400 604,
Maharashtra, India
Tel.: +91 22 41703200
Fax: +91-22 25835159
Website: www.advancedenzymes.com
CIN No: L24200MH1989PLC051018
www.advancedenzymes.com